Alpha-1 antitrypsin augmentation is indicated for COPD due to which underlying cause?

• A. It is used for all COPD patients
• B. It is indicated for COPD due to alpha-1 antitrypsin deficiency
• C. It cures COPD
• D. It is used only for bronchiectasis

Answer: (B)

Alpha-1 antitrypsin augmentation is a targeted therapy for COPD caused by inherited alpha-1 antitrypsin deficiency. The key idea is that alpha-1 antitrypsin (AAT) normally inhibits neutrophil elastase, protecting lung tissue from proteolytic damage. When AAT is deficient, elastase activity goes unchecked, leading to early and rapid emphysema, often in the lower lungs. In patients with COPD due to this deficiency, giving intravenous AAT raises circulating levels and helps restore elastase inhibition, slowing the decline in lung function. This treatment is not for all COPD patients or for bronchiectasis, and it does not cure COPD; it specifically addresses disease caused by AAT deficiency.